Despite the promising potential of Hsp90 inhibitors, their clinical application faces several challenges. One major issue is toxicity; since Hsp90 is also important for normal cell function, its inhibition can lead to adverse side effects. Additionally, cancer cells can develop resistance to Hsp90 inhibitors through various mechanisms, such as upregulating compensatory chaperones like Hsp70. Understanding and overcoming these challenges is essential for the successful clinical translation of Hsp90 inhibitors.
